2 Comments
User's avatar
Katerina Roznik's avatar

Great edition! Given the need for vastly larger datasets to improve AI’s predictive power, I wonder if AI will have to work hand in hand with traditional drug discovery techniques to fully realize its potential. the way companies like Absci are combining generative AI with cutting edge cancer research seems to be a promising step in this direction.

Andrii Buvailo, PhD's avatar

Thank you for your comment. You are right. I would reiterate it even stronger, the essence of AI "revolution" is not so much in the algorithms (they are sure thing important, but they are already sufficiently powerful for a broad range of tasks), but in 1) datasets 2) existing and new methods to generate more quality data faster.

Everything about AI in bio is actually about biological and clinical data.

Those companies who can create original data internally or have a grip on uniqu proprietary datasets -- have enourmous leverage to move faster and in non-linear ways.

From what I know about Absci, this company is a good candidate to be called "AI-driven," it seems to have all needed components to make it.